The new open-label phase 2a trial will look at the use of an oral formulation of synthetic psilocybin and evaluate its safety and efficacy in a small number of patients with fibromyalgia.
The psychedelic drug psilocybin, a naturally occurring compound found in some mushrooms, has been shown to initiate an immediate and long-lasting increase in neural connections in mice.
The researchers also found that the drug increased the complexity of only certain brain states, known as segregated brain states.
Analytical Cannabis spoke to Jerrold F. Rosenbaum, director of the Center for the Neuroscience of Psychedelics, to learn more about its research ambitions.
The new study examined structural changes in the brain that might explain psilocybin’s enduring antidepressant effects.
Results from a new clinical trial indicate that inhaling a mixture of 25 percent nitrous oxide and oxygen can provide long-lasting relief to those who have found other antidepressants ineffective.
Ketamine can provide rapid antidepressant relief in as little as two hours that can be sustained for days to weeks.
The survey also found that 75 percent of respondents now support cannabis legalization for all purposes, with just 5 percent opposed to both recreational and medical legalization.